Kintor Pharmaceutical Ltd (HK:9939) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kintor Pharmaceutical Ltd has successfully enrolled its first subject in the Phase III pivotal clinical trial of KX-826 tincture for treating male androgenetic alopecia in China. This trial, involving 25 clinical research centers and 666 patients, aims to assess the efficacy and safety of the 1.0% solution, expected to enhance clinical results compared to previous formulations. The study is anticipated to conclude by the end of 2025, marking a significant step for Kintor in the dermatology market.
For further insights into HK:9939 stock, check out TipRanks’ Stock Analysis page.